GBIM:OTCMKTS
GlobeImmune Inc
$0.00010
0.00%
(0.00) 1 دن
29 ستمبر, 3:48:52 PM GMT -4 · USD
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoGBIM کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
مارکیٹ کی سرمایہ کاری
580.00
اوسط والیوم
1.74 ہزار
والیوم
0.00
52 ہفتے میں اعلی
$0.04
52 ہفتے کا کم
$0.00
بقایہ شیئرز
57.52 لاکھ
ملازمین کی تعداد
22
مارکیٹ کی سرمایہ کاری
580.00
اوسط والیوم
1.74 ہزار
والیوم
0.00
52 ہفتے میں اعلی
$0.04
52 ہفتے کا کم
$0.00
بقایہ شیئرز
57.52 لاکھ
ملازمین کی تعداد
22
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
medwatch.com
·
6 منٹ پہلے
Iambic Therapeutics raises USD 150m in Nasdaq IPO
StreetInsider
·
11 منٹ پہلے
Global S&P Futures mixed in premarket
The Daily News | Texas' Oldest Newspaper
·
40 منٹ پہلے
FILE PHOTO: Traders work on the floor of the New York Stock Exchange (NYSE) in New York City
Yahoo Finance
·
2 گھنٹے پہلے
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
پروفائل
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc کے بارے میں
CEO-
ملازمین22
تاریخ قیام1 جنوری، 1995
ہیڈ کواٹرزلوئیزویل, کولوراڈو, ریاستہائے متحدہ
سیکٹر-
ویب سائٹglobeimmune.com